VivoSeq
Oncology

Pancreatic Cancer

860

Pipeline Programs↗

361

Active Trials↗

239

Companies Involved↗

Pancreatic Cancer is a highly competitive landscape with 860 programs across 239 companies. The most active players are BioNTech Research & Development, Inc., OSI Pharmaceuticals, Panbela Therapeutics, Inc.. 26 therapies are approved with 96 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

100/100

Pipeline Velocity

83/100

Mech. Concentration

4/100

Completion Rate

72/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

BioNTech Research & Development, Inc.

2 programs

Phase 1O

OSI Pharmaceuticals

1 program

Phase 1P

Panbela Therapeutics, Inc.

1 program

Phase 1B

Betta Pharmaceuticals Co., Ltd.

1 program

Phase 1Biogen logo

Biogen

1 program

Phase 1Sunshine Lake Pharma Co., Ltd. logo

Sunshine Lake Pharma Co., Ltd.

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical63

Methylprednisolone

Pfizer

Gemcitabine Hydrochloride

Gynecologic Oncology Group

Active Comparator

Moderna

Iohexol

GE Healthcare

Exenatide

AstraZeneca

Phase 1194

RAS(ON) Multi Inhibitor

Revolution Medicines

Lidocaine Hydrochloride

Citius Pharmaceuticals, Inc.

Talimogene Laherparepvec

Amgen

Pemetrexed Disodium

Gynecologic Oncology Group

Canakinumab

Novartis

Phase 2481

Belzutifan

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

PD-1

Sichuan Baili Pharmaceutical Co., Ltd.

Paricalcitol

AbbVie

Docetaxel

Avyxa

Osimertinib

AstraZeneca

Phase 396

Zolbetuximab

Astellas

Nab-Paclitaxel

Bristol-Myers Squibb

Gemcitabine

Johnson & Johnson

Olaparib

AstraZeneca

Oxaliplatin

Teva

Approved26

Selpercatinib

Eli Lilly

Sotorasib

Amgen

Dexamethasone

Aspen Global Incorporated

Bosutinib

Prism Pharmaceuticals

Vandetanib

Genzyme, a Sanofi Company

Analysis

Modality Breakdown

86%

Small molecule

834 of 966 classified programs — the dominant modality here.

14%ALL OTHERSMonoclonal antibody647%Cell therapy232%Vaccine232%Protein / enzyme101%Peptide6<1%Gene therapy3<1%Other3<1%

Small molecule leads; the ring shows all 966 classified programs, each share of the total. Modality classified for 99% of 1,064 pipeline programs.

Analysis

Trial Status

1,354

clinical trials

Completed582 · 43%
Recruiting189 · 14%
Unknown status177 · 13%
Terminated169 · 12%
Active, not recruiting89 · 7%
Not yet recruiting82 · 6%
Other66 · 5%

Clinical Trials

Trial Activity

1354 trials

Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer
Recruiting·JJiangsu Healthy Life Innovation Medical Technology Co., Ltd·Phase 3·NCT05653453·512 enrolled
DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer
Recruiting·HHopital Foch·Phase 2·NCT06757244·35 enrolled
Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer
Recruiting·UUniversity of Virginia·Phase 1/2·NCT06479239·23 enrolled
Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer
Recruiting·UUniversity of Kansas Medical Center·Phase 1/2·NCT06736717·21 enrolled
Adapted Guided Stereotactic Body Radiotherapy Combined with Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)
Recruiting·SShandong Cancer Hospital and Institute·Phase 1/2·NCT06844422·37 enrolled
Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)
Recruiting·AAmsterdam UMC, location VUmc·Phase 1/2·NCT06384560·66 enrolled
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT06782932·38 enrolled
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
Recruiting·EEleison Pharmaceuticals LLC.·Phase 3·NCT01954992·480 enrolled
A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer
Recruiting·WWest China Hospital·Phase 2·NCT07101679·23 enrolled
A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation
Recruiting·SSun Yat-sen University·Phase 1·NCT06898385·9 enrolled
Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer
Recruiting·RRuijin Hospital·Phase 1·NCT05916261·54 enrolled
mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients
Recruiting·SSun Yat-sen University·Phase 2·NCT04084496·80 enrolled
A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
Recruiting·AAkeso·Phase 3·NCT06953999·999 enrolled
Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer
Recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT07238283·662 enrolled
Namodenoson Treatment of Advanced Pancreatic Cancer
Recruiting·CCan-Fite BioPharma·Phase 2·NCT06387342·20 enrolled
Page 1 of 91

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)